Cover Image
市場調查報告書

復發性惡性神經膠質瘤:全球臨床實驗檢討

Recurrent Malignant Glioma Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 299733
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
復發性惡性神經膠質瘤:全球臨床實驗檢討 Recurrent Malignant Glioma Global Clinical Trials Review, H2, 2016
出版日期: 2016年10月31日 內容資訊: 英文 148 Pages
簡介

本報告提供復發性惡性神經膠質瘤相關臨床研究最新趨勢相關分析,以疾病概要為首,提供地區及主要國家的臨床實驗狀況,Phase別·各進展狀況臨床實驗資料,被實驗者的募集情況,有潛力的贊助商,並彙整各企業·研究機關臨床實驗簡介等資訊,為您概述為以下內容。

目錄

簡介

  • 復發性惡性神經膠質瘤
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數和平均實驗人數
    • 亞太地區的主要國家
    • 歐洲的主要5個國家
    • 北美的主要國家
    • 中東非洲的主要國家
    • 中南美的主要國家

在G7各國臨床實驗

在G7各國臨床實驗:Phase別

在G7各國臨床實驗:各進展狀況

在E7各國臨床實驗

在E7各國臨床實驗:Phase別

在E7各國臨床實驗:各進展狀況

Phase別臨床實驗

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗

一定期間所採用的實驗對象

贊助商的不同種類的臨床實驗

有潛力的贊助商

  • 參加復發性惡性神經膠質瘤治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • Insys Therapeutics, Inc.
    • Merck & Co., Inc.
    • Eisai
    • TransMolecular, Inc.
    • Eli Lilly and Company
    • to-BBB technologies BV
    • Tactical Therapeutics, Inc
    • Shandong Lanjin Pharmaceuticals Co. Ltd
    • Direct Therapeutics, Inc.
    • Amgen Inc.
  • 有代表性的醫院·研究機關臨床實驗概要
    • National Cancer Institute
    • Duke University
    • Memorial Sloan Kettering Cancer Center
    • North American Brain Tumor Consortium
    • The University of Texas M. D. Anderson Cancer Center
    • Northwestern University
    • UCLA's Jonsson Comprehensive Cancer Center
    • Sidney Kimmel Comprehensive Cancer Center
    • University of Colorado
    • Wake Forest University

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3874CTIDB

GlobalData's clinical trial report, "Recurrent Malignant Glioma Global Clinical Trials Review, H2, 2016" provides an overview of Recurrent Malignant Glioma clinical trials scenario. This report provides top line data relating to the clinical trials on Recurrent Malignant Glioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

  • List of Tables
  • List of Figures
  • Report Guidance
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Disclaimer
  • Source

List of Tables

  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region, 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016*
  • Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top